ESC 365 - Impact of CYP2C19 genotype status on clinical outcomes in patients with symptomatic coronary artery disease, stroke, and peripheral arterial disease

ESC Professional Premium Access

Impact of CYP2C19 genotype status on clinical outcomes in patients with symptomatic coronary artery disease, stroke, and peripheral arterial disease

Session: Pharmacogenetics: a tool to guide clinical decisions

Topic: Pharmacogenetics

Speaker: Ms D. Maas (Nijmegen, NL)

Event: ESC Congress 2023

Congress Presentation

Add to my library

About the speaker

Ms Dominique Maas

Radboud University Medical Centre, Nijmegen (Netherlands (The))

0 follower

4 more presentations in this session

The clinical implementation of a de-escalation strategy using CYP2C19 genotyping in patients with an acute coronary syndrome: insights from the FORCE-ACS registry

Speaker: Doctor J. Azzahhafi (Nieuwegein, NL)

Genome-wide association study of amidoarone-induced hypothyroidism

Speaker: Mr S. Rand (Copenhagen, DK)

Arg389Gly beta-1-adrenergic receptor polymorphism determines neutrophil-stunning-associated cardioprotection by metoprolol

Speaker: Mr A. Clemente Moragon (Madrid, ES)

SLCO1B1*5 is protective against non-senile cataracts in cohort prescribed statins: analysis in a British-South Asian cohort

Speaker: Doctor E. Magavern (London, GB)

Access the full session

Pharmacogenetics: a tool to guide clinical decisions

Speakers: Ms D. Maas, Doctor J. Azzahhafi, Mr S. Rand, Mr A. Clemente Moragon, Doctor E. Magavern

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources